Roche withdraws checkpoint blocker from the market
Roche AGs US subsidiary Genentech Inc has withdrawn its checkpoint inhibitor atezolizumab from the market after disappointing results in bladder cancer.
Author Archive for: TG
About Thomas Gabrielczyk
This author has not written his bio yet.
But we are proud to say that Thomas Gabrielczyk contributed 1247 entries already.
Entries by Thomas Gabrielczyk
ExeVir receives EIB risk finance for multiple COVID-19 nanobody
/in News/by Thomas GabrielczykWith the help of a 25m loan from the European Investment Bank, ExeVir BIO BV will advance clinical trials with its COVID-19 nanobody XVR012.
Hummingbird and Synaffix in $150m ADC deal
/in News/by Thomas GabrielczykRational antibody design specialist Hummingbird Bioscience has licenced a cancer target and the modular ADC technology of Dutch Synaffix BV.
Ethris inks 15m deal with Indian Ciplas
/in News/by Thomas GabrielczykCipla EU Ltd is going to make an equity investment of 15m in Ethris GmbH, a specialist for respiratory delivery of therapeutic mRNAs.
First hints for leukopenia diagnostic in MS
/in News/by Thomas GabrielczykScientists from the University of Basel and the University Hospital Basel have found that two bacterial species may indicate multiple sclerosis-associated lymphopenia.
Numares AG cashes in 20m from EIB
/in News/by Thomas GabrielczykThe European Investment Bank (EIB) is going to support the AI-platform of NMR/metabolomics diagnostics company Numares AG to improve disease prediction.
Amgen wins race of top `22 deals with $26bn for Horizon thx
/in News/by Thomas GabrielczykAccording to Bloomberg, the US biotechnology giant Amgen plans to buy Horizon Therapeutics at a valuation of about $26bn. Overall, the deal corresponds to an enterprise value including debt of […]
European Commission calls for reversal of Illumina’s $7bn Grail merger
/in News/by Thomas GabrielczykThe European Commission has now recommended concrete steps that, while not yet final, would require Illumina to "swiftly" reverse its controversial $7.1bn acquisition of Grail.
BioNTech and Ryvu Therapeutics enter into global collaboration
/in News/by Thomas GabrielczykRenewed focus on cancer: COVID-19 vaccine company BioNTech SE (Nasdaq: BNTX) and Ryvu Therapeutics S.A., located in Krakow (Warsaw Stock Exchange: RVU), a Polish clinical-stage cancer therapeutics development company, announced […]
Amsterdam Neogene Therapeutics aquired by AstraZeneca
/in News/by Thomas GabrielczykAstraZeneca announced an agreement to acquire Neogene Therapeutics Inc. (Neogene), a global clinical-stage biotechnology company spezialised in next-generation T-cell receptor therapies (TCR-Ts) that offer a novel cell therapy approach for […]